Naveen Pemmaraju, MD is Professor in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, Texas. He is the inaugural Director of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program, the Co-Section Head of the MPN Section, and additionally serves as Executive Director for Cancer Medicine for the MDACC Cancer Network. Dr Pemmaraju is a world-leading clinical/translational researcher and known as a worldrenowned speaker in the area of rare myeloid malignancies including BPDCN, MPN, and AML and has served as lead national/international PI on numerous key clinical trials in the field. Dr Pemmaraju’s leadership led to the approval of the first targeted therapy specifically approved in BPDCN in December 2018 (CD123-targeted therapy, tagraxofusp, Pemmaraju et al NEJM April 2019). He has authored/coauthored over 450+ papers in the medical literature and has served as the lead PI for 2 separate DOD grants. In addition, Dr Pemmaraju is a well-regarded clinician and highly sought after medical educator, having been awarded the Gerald P. Bodey Excellence in Teaching Award at MDACC in 2020, the MPN Hero Award in 2022, the Faculty Educator of the Year in 2023 for MDACC and the MDACC Community Outreach Faculty Excellence Award in 2023.